NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JAPIC ID: JapicCTI-101084

Registered date:

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiednon-infectiouse uveitis
Date of first enrollment26/4/2010
Target sample size208
Countries of recruitment
Study typeINTERVENTIONAL
Intervention(s)Intervention name : AIN457 Dosage And administration of the intervention : subcutaneous injection Control intervention name : null

Outcome(s)

Primary Outcomemean change in vitreous haze grade in the study eye from baseline to 28 weeks
Secondary Outcomechange in immunosuppressive medication score from baseline to Week 28

Key inclusion & exclusion criteria

Age minimum18
Age maximum
GenderBOTH
Include criteria- Male and female subjects 18 years of age or older - Patients with diagnosis of chronic non-infectious intermediate uveitis, posterior uveitis or panuveitis in at least one eye - Evidence of active intermediate, posterior or panuveitis at screening and baseline in at least one eye - Requirement for any of the immunosuppressive therapies for the treatment or prevention of uveitis
Exclude criteria- Patients with a primary diagnosis of Behcet's disease or anterior uveitis - Any intermediate uveitis, posterior uveitis or panuveitis in which the manifestation(s) of the active intraocular inflammatory disease may spontaneously resolve or that are not characterized by the presence of either anterior chamber cells or vitritis such as the white dot retino-choroidopathies - Patients with infectious uveitis

Related Information

Contact

public contact
Name Novartis Pharma K.K. Novartis Direct
Address 0120-003-293
Telephone
E-mail
Affiliation
scientific contact
Name
Address
Telephone
E-mail
Affiliation